CEMI - ケムバイオ・ダイアグノスティクス (Chembio Diagnostics Inc.) ケムバイオ・ダイアグノスティクス

 CEMIのチャート


 CEMIの企業情報

symbol CEMI
会社名 Chembio Diagnostics Inc (ケムバイオ・ダイアグノスティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Chembio Diagnostics Inc. (Chembio) and its subsidiary Chembio Diagnostic Systems Inc. develop manufacture market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples and are manufactured in a standard cassette format a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.   ケムバイオ・ダイアグノスティクスは、米国の検査製品メ―カ―。感染症を検出するポイントオブケアの診断テストを開発、製造、販売、またライセンス供与を行う。主な製品には、ヒト免疫不全ウイルス(HIV)抗体検出テスト(カセット形式、ディップスティック形式、バレル形式)、梅毒検出テスト、イヌのリ―シュマニア症検出テストなどがある。   
本社所在地 3661 Horseblock Road Medford NY 11763 USA
代表者氏名 John J. Sperzel ジョン・J.・スペルゼル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 631-924-1135
設立年月日 31382
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 165人
url www.chembio.com
nasdaq_url https://www.nasdaq.com/symbol/cemi
adr_tso
EBITDA EBITDA(百万ドル) -4.13082
終値(lastsale) 9.7
時価総額(marketcap) 137484114
時価総額 時価総額(百万ドル) 136.77540
売上高 売上高(百万ドル) 30.01290
企業価値(EV) 企業価値(EV)(百万ドル) 127.69617
当期純利益 当期純利益(百万ドル) -4.96381
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Chembio Diagnostics Inc revenues increased 57% to $16.4M. Net loss decreased 37% to $2.4M. Revenues reflect North America segment increase from $1.8M to $6M Africa segment increase from $863K to $3.9M. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $16K (expense) Interest Income increase of 44% to $30K (income).

 CEMIのテクニカル分析


 CEMIのニュース

   Royce & Associates reduced stake in Chembio Diagnostics Inc  2021/01/29 16:00:26 Investing.com
https://www.investing.com/news/stock-market-news/royce--associates-reduced-stake-in-chembio-diagnostics-inc-2403592
   Chembio Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
   Return On Capital Employed Overview: Chembio Diagnostics  2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI)  2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
   Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI)  2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
   Chembio Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
   Return On Capital Employed Overview: Chembio Diagnostics  2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI)  2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
   Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI)  2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
   Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders  2020/07/16 18:32:00 Business Wire
SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)---- $CEMI #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2020 and June 16, 2020. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. If you suffered a loss as a result of Chembio'
   Chembio Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
   Return On Capital Employed Overview: Chembio Diagnostics  2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI)  2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
   Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI)  2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
   Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders  2020/07/16 18:32:00 Business Wire
SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)---- $CEMI #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2020 and June 16, 2020. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. If you suffered a loss as a result of Chembio'

 関連キーワード  (医薬品 米国株 ケムバイオ・ダイアグノスティクス CEMI Chembio Diagnostics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)